Company earns recognition among top digital experience platforms in the market BURLINGTON, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Progress Software (Nasdaq: PRGS) today announced its inclusion as one of nine vendors in The Forrester Wave™: Digital Experience Platforms, Q4 20251, marking its debut in this influential analyst report. Progress sees this recognition as a reflection of its growing influence in the digital experience platform (DXP) market and its commitment to delivering secure, scalable, perso ...

Core Points - The Baltic Horizon Fund held a repeat extraordinary General Meeting on December 16, 2025, in Tallinn, Estonia, due to insufficient quorum at the initial meeting on December 8, 2025 [1][2] - A total of 58,923,830 units, representing 41.05% of the total votes in the fund, were present at the meeting [3] - The main agenda was to approve the issuance of new units in Q1 2026 to strengthen the fund's balance sheet, which was passed with 92.94% of the votes in favor [4]

AUSTIN, Texas, Dec. 16, 2025 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC: GTVH) announces it has signed a Letter of Intent (LOI) to lease a canning and manufacturing facility that will serve as the company’s central hub for beverage production, brand development, and private-label services. The planned facility will support GTVH’s strategy to build a streamlined platform where new and existing brands can be developed, produced, and prepared for market under one operation. A Practical, ...

DENVER, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions (NYSE American: SRXH): A Strategic Pivot Toward Gen2 Digital Treasuries SRx Health Solutions (NYSE American: SRXH) headlines the morning with a definitive agreement to acquire EMJ Crypto Technologies (EMJX), marking a transformative shift from traditional healthcare operations toward a next-generation digital-asset treasury platform. The transaction positions SRXH at the intersection of public-market governance and quantitative, AI-enabled trea ...

Core Viewpoint - Akari Therapeutics has announced a definitive agreement for the issuance and sale of approximately 12.6 million American Depositary Shares (ADSs) and unregistered warrants, with significant participation from its Directors, Officers, and Executive Management, aimed at supporting its oncology drug development initiatives and improving its capital structure [1][4][6]. Group 1: Offering Details - The offering includes 10,043,774 ADSs in a registered direct offering priced at $0.3883 per ADS, along with unregistered Series G warrants [3]. - A concurrent private placement will issue unregistered pre-funded warrants for 2,563,713 ADSs at a combined price of $0.4041 per ADS [3]. - The gross proceeds from the offering are expected to be around $5 million, with over $1 million coming from new cash investments by the Company's Directors, Officers, and Executive Management [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for ongoing research and development, working capital, and general corporate purposes [4]. Group 3: Debt Conversion - Existing note holders have agreed to convert approximately $2.5 million of the Company's outstanding debt into unregistered pre-funded warrants and warrants to purchase 6,409,410 ADSs at a combined exchange price of $0.4041 per ADS [5]. Group 4: Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs), with its lead candidate AKTX-101 targeting the Trop2 receptor on cancer cells [10]. - The novel payload PH1 is designed to disrupt RNA splicing within cancer cells, showing significant activity and prolonged survival in preclinical studies compared to traditional ADCs [10].

HAUPPAUGE, N.Y., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced that Dime has awarded a grant to Accompany Capital in support of their mission to help underserved entrepreneurs succeed by empowering them to create jobs, stimulate economic growth, and boost New York City communities. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime ...

Core Insights - Can-Fite BioPharma Ltd. is advancing its clinical development activities and financial status, focusing on proprietary small-molecule drugs for oncological and inflammatory diseases [1] Clinical Development - Can-Fite is enrolling patients in a pivotal Phase III clinical study for Namodenoson, targeting advanced hepatocellular carcinoma (HCC) in patients with Child-Pugh B7 liver function, addressing a significant unmet medical need [2] - An interim analysis for the Phase III study of Namodenoson is expected in Q4 2026, with potential eligibility for conditional regulatory approval from the FDA and EMA based on positive results [2] - A Phase IIb clinical study of Namodenoson for metabolic dysfunction-associated steatohepatitis (MASH) is ongoing, following positive Phase IIa trial results [3] - Namodenoson is also being evaluated in a Phase IIa study for pancreatic cancer, with data expected in Q2 2026 [4] - Can-Fite is conducting a pivotal Phase III clinical study for Piclidenoson in psoriasis, with interim analysis data anticipated in Q2 2026 [5] - The company has developed a Phase II study protocol for Lowe Syndrome, planning to submit it to regulatory authorities in Italy and EMA in Q1 2026 [5] Financial Status - As of June 30, 2025, Can-Fite had cash and cash equivalents of $6.45 million, and raised $5 million from a public offering in July 2025, followed by an additional $2.2 million through an ATM facility in November 2025 [6] Company Strategy - The company aims to address significant unmet medical needs with orally administered drug candidates, with ongoing pivotal studies in liver cancer and psoriasis, alongside mid-stage programs in MASH and pancreatic cancer [7] - Can-Fite's lead drug candidate, Piclidenoson, is positioned in multi-billion-dollar markets for cancer, liver, and inflammatory diseases, with a strong safety profile demonstrated in over 1,600 patients [8]

Core Viewpoint - INVL Baltic Farmland has outlined its schedule for publishing financial information to investors in 2026, indicating a structured approach to transparency and communication with stakeholders [1]. Group 1: Financial Reporting Schedule - The company plans to release audited financial reports and an annual management report from February 27 to March 1, 2026 [1]. - Preliminary operating results and a factsheet for the first three months of 2026 will be published on May 19, 2026 [1]. - A semi-annual management report for 2026 is scheduled for August 18, 2026 [1]. - Preliminary operating results and a factsheet for the first nine months of 2026 will be available on November 17, 2026 [1]. Group 2: Contact Information - The authorized person for providing additional information is Director Egle Surpliene, who can be contacted via email at egle.surpliene@invaldainvl.com [2].

Core Viewpoint - The national memorial ceremony for the Nanjing Massacre victims was held on December 13, 2025, emphasizing the importance of remembering history and fostering peaceful exchanges between nations [1][2]. Group 1: Ceremony Details - The memorial ceremony took place at the Memorial Hall of the Victims in Nanjing, attended by international guests who participated in a "Candlelight Memorial" to honor the victims [1][3]. - Notable attendees included Sayoko Yamauchi from Japan, Christoph Reinhardt, the great-grandson of John Rabe, and Friedrich Rosen, grandson of Georg Rosen, highlighting international recognition of the event [3]. Group 2: Personal Reflections - Sayoko Yamauchi expressed the need for Japanese society to preserve the memory of the victims and learn from history, advocating for peaceful exchanges between Japan and China [4]. - Christoph Reinhardt donated significant archives to the memorial, including a bronze plaque with the names of John Rabe and his wife, illustrating the ongoing impact of historical events on descendants [5]. - Friedrich Rosen shared insights about his grandfather's efforts during the Nanjing Massacre, emphasizing the importance of acknowledging past atrocities while reflecting on personal family history [6].

MCLEAN, Va., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity and AI-driven solutions, today announced its selection to the 2025 MSSP 250 ranking. The Company now stands among the world’s top leading managed security services providers, according to MSSP Alert, a CyberRisk Alliance resource. Cycurion earned a placement in the top 50%, debuting at No. 116. This marks the Company’s first year being evaluated for this prestigiou ...